Based on biomarker expression, pathological analyses define malignancies as positive for estrogen receptor (ER), progesterone receptor (PR), and HER2, or as negative for all three markers (triple-negative breast cancer, TNBC). Here, ESR1 is linked to triple-negative breast carcinoma.